Related Experiment Video
Updated: May 9, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Prognostic and predictive molecular biomarkers in colorectal cancer
Jianzhi Zhang1,2, Hao Zhu3, Wentao Liu4
1Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Abstract:
Precision medicine has brought revolutionary changes to the diagnosis and treatment of cancer patients, and is currently a hot and challenging research topic. Currently, the treatment regimens for most colorectal cancer (CRC) patients are mainly determined by several biomakers, including Microsatellite Instability (MSI), RAS, and BRAF. However, the roles of promising biomarkers such as HER-2, consensus molecular subtypes (CMS), and circulating tumor DNA (ctDNA) in CRC are not yet fully clear. Therefore, it is urgent to explore the potential of these emerging biomarkers in the diagnosis and treatment of CRC patients. In this paper, we discuss recent advances in CRC biomarkers, especially clinical data, and focus on the roles of biomarkers in prognosis, prediction, treatment strategies, and the intrinsic connections with clinical pathological features, hoping to promote better precision medicine for colorectal cancer.
Insights
Emerging biomarkers like HER-2, CMS, and ctDNA show promise for improving colorectal cancer (CRC) diagnosis and treatment. Further research is crucial for advancing precision medicine in CRC.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Precision medicine is revolutionizing cancer care.
- Current colorectal cancer (CRC) treatment relies on biomarkers like MSI, RAS, and BRAF.
- The clinical utility of novel biomarkers in CRC requires further elucidation.
Purpose of the Study:
- To review recent advances in colorectal cancer (CRC) biomarkers.
- To focus on the roles of emerging biomarkers (HER-2, CMS, ctDNA) in CRC.
- To explore biomarker connections with clinical pathology for improved precision medicine.
Main Methods:
- Literature review of recent advances in CRC biomarkers.
- Analysis of clinical data related to biomarker roles.
- Discussion of prognostic and predictive biomarker applications.
Main Results:
- Established biomarkers (MSI, RAS, BRAF) guide current CRC treatment.
- Emerging biomarkers (HER-2, CMS, ctDNA) have unclear roles but significant potential.
- Biomarker roles are linked to prognosis, prediction, and treatment strategies.
Conclusions:
- There is an urgent need to explore novel biomarkers for CRC.
- Understanding emerging biomarkers will enhance precision medicine for CRC patients.
- Integrating biomarker data with clinical features is key for tailored CRC therapies.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
15:17Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
